Lipotoxicity and steatohepatitis in an overfed mouse model for non-alcoholic fatty liver disease

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1812, Issue 4, 2011, Pages 447-458

  Gaemers, Ingrid C ^a   Stallen, Jan M ^a   Kunne, Cindy ^a   Wallner, Christian ^a   van Werven, Jochem ^a   Nederveen, Aart ^a   Lamers, Wouter H ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Adipose tissue; Endoplasmatic reticulum stress; High fat diet; Liver; Non alcoholic fatty liver disease; Overnutrition; Steatohepatitis

Indexed keywords

ADIPONECTIN; CD36 ANTIGEN; FATTY ACID BINDING PROTEIN; FIBROBLAST GROWTH FACTOR 21; GLYCOGEN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENDOPLASMIC RETICULUM STRESS; GENE EXPRESSION; HISTOPATHOLOGY; HYPERINSULINEMIA; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LIPID DIET; LIPOTOXICITY; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUBE FEEDING; WESTERN BLOTTING; WHITE ADIPOSE TISSUE;

ADIPOSE TISSUE; ANIMALS; DIETARY FATS; DISEASE PROGRESSION; FATTY ACID-BINDING PROTEINS; FATTY LIVER; HYPERINSULINISM; INFLAMMATION; LIPOGENESIS; LIVER; MALE; MICE; MICE, INBRED C57BL; ORGAN SIZE; OVERNUTRITION; PPAR GAMMA;

MUS;

EID: 79151469687     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbadis.2011.01.003     Document Type: Article

References (53)

1. Larter C.Z., Yeh M.M. Animal models of NASH: getting both pathology and metabolic context right. J. Gastroenterol. Hepatol. 2008, 23:1635-1648.
2. Wanless I.R., Lentz J.S. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990, 12:1106-1110.
3. Kleiner D.E., Brunt E.M., Van N.M., Behling C., Contos M.J., Cummings O.W., Ferrell L.D., Liu Y.C., Torbenson M.S., Unalp-Arida A., Yeh M., McCullough A.J., Sanyal A.J. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005, 41:1313-1321.
4. Day C.P., James O.F. Hepatic steatosis: innocent bystander or guilty party?. Hepatology 1998, 27:1463-1466.
5. Berson A., De, V B., Letteron P., Robin M.A., Moreau C., El K.J., Verthier N., Feldmann G., Fromenty B., Pessayre D. Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes. Gastroenterology 1998, 114:764-774.
6. Yang S.Q., Lin H.Z., Lane M.D., Clemens M., Diehl A.M. Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:2557-2562.
7. Syn W.K., Yang L., Chiang D.J., Qian Y., Jung Y., Karaca G., Choi S.S., Witek R.P., Omenetti A., Pereira T.A., Diehl A.M. Genetic differences in oxidative stress and inflammatory responses to diet-induced obesity do not alter liver fibrosis in mice. Liver Int. 2009, 29:1262-1272.
8. Neuschwander-Tetri B.A. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology 2010, 52:774-788.
9. Lee Y., Hirose H., Ohneda M., Johnson J.H., McGarry J.D., Unger R.H. Beta-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: impairment in adipocyte-beta-cell relationships. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:10878-10882.
10. Malhi H., Gores G.J. Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Semin. Liver Dis. 2008, 28:360-369.
11. Puri P., Baillie R.A., Wiest M.M., Mirshahi F., Choudhury J., Cheung O., Sargeant C., Contos M.J., Sanyal A.J. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology 2007, 46:1081-1090.
12. Donnelly K.L., Smith C.I., Schwarzenberg S.J., Jessurun J., Boldt M.D., Parks E.J. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J. Clin. Invest. 2005, 115:1343-1351.
13. Nielsen S., Guo Z., Johnson C.M., Hensrud D.D., Jensen M.D. Splanchnic lipolysis in human obesity. J. Clin. Invest. 2004, 113:1582-1588.
14. Musso G., Gambino R., Cassader M. Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD). Prog. Lipid Res. 2009, 48:1-26.
15. Pickens M.K., Yan J.S., Ng R.K., Ogata H., Grenert J.P., Beysen C., Turner S.M., Maher J.J. Dietary sucrose is essential to the development of liver injury in the methionine-choline-deficient model of steatohepatitis. J. Lipid Res. 2009, 50:2072-2082.
16. Lazo M., Clark J.M. The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin. Liver Dis. 2008, 28:339-350.
17. Deng Q.G., She H., Cheng J.H., French S.W., Koop D.R., Xiong S., Tsukamoto H. Steatohepatitis induced by intragastric overfeeding in mice. Hepatology 2005, 42:905-914.
18. Srivastava N.K., Pradhan S., Mittal B., Kumar R., Gowda G.N. An improved, single step standardized method of lipid extraction from human skeletal muscle tissue. Anal. Lett. 2006, 39:297-315.
19. Ruijter J.M., Ramakers C., Hoogaars W.M., Karlen Y., Bakker O., van den Hoff M.J., Moorman A.F. Amplification efficiency: linking baseline and bias in the analysis of quantitative PCR data. Nucleic Acids Res. 2009, 37:e45.
20. Ruijter J.M., Thygesen H.H., Schoneveld O.J., Das A.T., Berkhout B., Lamers W.H. Factor correction as a tool to eliminate between-session variation in replicate experiments: application to molecular biology and retrovirology. Retrovirology 2006, 3:2.
21. Browning J.D., Horton J.D. Molecular mediators of hepatic steatosis and liver injury. J. Clin. Invest. 2004, 114:147-152.
22. Gavrilova O., Haluzik M., Matsusue K., Cutson J.J., Johnson L., Dietz K.R., Nicol C.J., Vinson C., Gonzalez F.J., Reitman M.L. Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J. Biol. Chem. 2003, 278:34268-34276.
23. Dushay J., Chui P.C., Gopalakrishnan G.S., Varela-Rey M., Crawley M., Fisher F.M., Badman M.K., Martinez-Chantar M.L., Maratos-Flier E. Increased Fibroblast Growth Factor 21 in Obesity and Nonalcoholic Fatty Liver Disease. Gastroenterology 2010, 139:456-463.
24. Yilmaz Y., Eren F., Yonal O., Kurt R., Aktas B., Celikel C.A., Ozdogan O., Imeryuz N., Kalayci C., Avsar E. Increased Serum FGF21 Levels in Patients with Nonalcoholic Fatty Liver Disease. Eur. J. Clin. Invest. 2010, 40:887-892.
25. Uyeda K., Repa J.J. Carbohydrate response element binding protein, ChREBP, a transcription factor coupling hepatic glucose utilization and lipid synthesis. Cell Metab. 2006, 4:107-110.
26. Brown K.E., Brunt E.M., Heinecke J.W. Immunohistochemical detection of myeloperoxidase and its oxidation products in Kupffer cells of human liver. Am. J. Pathol. 2001, 159:2081-2088.
27. Malaguarnera L., Madeddu R., Palio E., Arena N., Malaguarnera M. Heme oxygenase-1 levels and oxidative stress-related parameters in non-alcoholic fatty liver disease patients. J. Hepatol. 2005, 42:585-591.
28. Chalasani N., Gorski J.C., Asghar M.S., Asghar A., Foresman B., Hall S.D., Crabb D.W. Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis. Hepatology 2003, 37:544-550.
29. Weltman M.D., Farrell G.C., Hall P., Ingelman-Sundberg M., Liddle C. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology 1998, 27:128-133.
30. Farombi E.O., Surh Y.J. Heme oxygenase-1 as a potential therapeutic target for hepatoprotection. J. Biochem. Mol. Biol. 2006, 39:479-491.
31. Scheuner D., Kaufman R.J. The unfolded protein response: a pathway that links insulin demand with beta-cell failure and diabetes. Endocr. Rev. 2008, 29:317-333.
32. Fukumura D., Ushiyama A., Duda D.G., Xu L., Tam J., Krishna V., Chatterjee K., Garkavtsev I., Jain R.K. Paracrine regulation of angiogenesis and adipocyte differentiation during in vivo adipogenesis. Circ. Res. 2003, 93:e88-e97.
33. Jenkins D.J., Kendall C.W., Keown-Eyssen G., Josse R.G., Silverberg J., Booth G.L., Vidgen E., Josse A.R., Nguyen T.H., Corrigan S., Banach M.S., Ares S., Mitchell S., Emam A., Augustin L.S., Parker T.L., Leiter L.A. Effect of a low-glycemic index or a high-cereal fiber diet on type 2 diabetes: a randomized trial. JAMA 2008, 300:2742-2753.
34. Baumgardner J.N., Shankar K., Hennings L., Badger T.M., Ronis M.J. A new model for nonalcoholic steatohepatitis in the rat utilizing total enteral nutrition to overfeed a high-polyunsaturated fat diet. Am. J. Physiol. Gastrointest. Liver Physiol. 2008, 294:G27-G38.
35. Buettner R., Parhofer K.G., Woenckhaus M., Wrede C.E., Kunz-Schughart L.A., Scholmerich J., Bollheimer L.C. Defining high-fat-diet rat models: metabolic and molecular effects of different fat types. J. Mol. Endocrinol. 2006, 36:485-501.
36. Ito M., Suzuki J., Tsujioka S., Sasaki M., Gomori A., Shirakura T., Hirose H., Ito M., Ishihara A., Iwaasa H., Kanatani A. Longitudinal analysis of murine steatohepatitis model induced by chronic exposure to high-fat diet. Hepatol. Res. 2007, 37:50-57.
37. Lieber C.S., Leo M.A., Mak K.M., Xu Y., Cao Q., Ren C., Ponomarenko A., DeCarli L.M. Model of nonalcoholic steatohepatitis. Am. J. Clin. Nutr. 2004, 79:502-509.
38. Zhang X., Yeung D.C., Karpisek M., Stejskal D., Zhou Z.G., Liu F., Wong R.L., Chow W.S., Tso A.W., Lam K.S., Xu A. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 2008, 57:1246-1253.
39. Memon R.A., Tecott L.H., Nonogaki K., Beigneux A., Moser A.H., Grunfeld C., Feingold K.R. Up-regulation of peroxisome proliferator-activated receptors (PPAR-alpha) and PPAR-gamma messenger ribonucleic acid expression in the liver in murine obesity: troglitazone induces expression of PPAR-gamma-responsive adipose tissue-specific genes in the liver of obese diabetic mice. Endocrinology 2000, 141:4021-4031.
40. Westerbacka J., Kolak M., Kiviluoto T., Arkkila P., Siren J., Hamsten A., Fisher R.M., Yki-Jarvinen H. Genes involved in fatty acid partitioning and binding, lipolysis, monocyte/macrophage recruitment, and inflammation are overexpressed in the human fatty liver of insulin-resistant subjects. Diabetes 2007, 56:2759-2765.
41. Wang H., Qiang L., Farmer S.R. Identification of a domain within peroxisome proliferator-activated receptor gamma regulating expression of a group of genes containing fibroblast growth factor 21 that are selectively repressed by SIRT1 in adipocytes. Mol. Cell. Biol. 2008, 28:188-200.
42. Matsuzawa N., Takamura T., Kurita S., Misu H., Ota T., Ando H., Yokoyama M., Honda M., Zen Y., Nakanuma Y., Miyamoto K., Kaneko S. Lipid-induced oxidative stress causes steatohepatitis in mice fed an atherogenic diet. Hepatology 2007, 46:1392-1403.
43. Anstee Q.M., Goldin R.D. Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. Int. J. Exp. Pathol. 2006, 87:1-16.
44. Kim J.Y., van de W.E., Laplante M., Azzara A., Trujillo M.E., Hofmann S.M., Schraw T., Durand J.L., Li H., Li G., Jelicks L.A., Mehler M.F., Hui D.Y., Deshaies Y., Shulman G.I., Schwartz G.J., Scherer P.E. Obesity-associated improvements in metabolic profile through expansion of adipose tissue. J. Clin. Invest. 2007, 117:2621-2637.
45. Larter C.Z., Yeh M.M., Van Rooyen D.M., Teoh N.C., Brooling J., Hou J.Y., Williams J., Clyne M., Nolan C.J., Farrell G.C. Roles of adipose restriction and metabolic factors in progression of steatosis to steatohepatitis in obese, diabetic mice. J. Gastroenterol. Hepatol. 2009, 24:1658-1668.
46. Medina-Gomez G., Gray S., Vidal-Puig A. Adipogenesis and lipotoxicity: role of peroxisome proliferator-activated receptor gamma (PPARgamma) and PPARgammacoactivator-1 (PGC1). Public Health Nutr. 2007, 10:1132-1137.
47. Wang M.Y., Grayburn P., Chen S., Ravazzola M., Orci L., Unger R.H. Adipogenic capacity and the susceptibility to type 2 diabetes and metabolic syndrome. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:6139-6144.
48. Fan J.G., Farrell G.C. VAT fat is bad for the liver, SAT fat is not!. J. Gastroenterol. Hepatol. 2008, 23:829-832.
49. Hu P., Han Z., Couvillon A.D., Kaufman R.J., Exton J.H. Autocrine tumor necrosis factor alpha links endoplasmic reticulum stress to the membrane death receptor pathway through IRE1alpha-mediated NF-kappaB activation and down-regulation of TRAF2 expression. Mol. Cell. Biol. 2006, 26:3071-3084.
50. Wang D., Wei Y., Pagliassotti M.J. Saturated fatty acids promote endoplasmic reticulum stress and liver injury in rats with hepatic steatosis. Endocrinology 2006, 147:943-951.
51. Puri P., Mirshahi F., Cheung O., Natarajan R., Maher J.W., Kellum J.M., Sanyal A.J. Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease. Gastroenterology 2008, 134:568-576.
52. Randle P.J., Garland P.B., Hales C.N., Newsholme E.A. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963, 1:785-789.
53. Manco M., Calvani M., Mingrone G. Effects of dietary fatty acids on insulin sensitivity and secretion. Diabetes Obes. Metab. 2004, 6:402-413.